Hansoh Pharmaceutical Group Co. Ltd. has won a green light for inebilizumab, approved by China’s NMPA for the treatment of adults with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive. The decision marked Hansoh’s first biologic approval.
Seeking to accelerate the company's long-term growth through an expansion of its rare disease pipeline, Horizon Therapeutics plc said Feb. 1 it will buy Viela Bio Inc. for $3.05 billion, or $53 per share (NASDAQ:VIE). Once closed, the deal would add a new commercial-stage asset, Uplizna (inebilizumab), to Horizon's portfolio alongside its current lead products, Tepezza (teprotumumab) for the treatment of thyroid eye disease and Krystexxa (pegloticase) for uncontrolled gout. Dublin-based Horizon, which had $2.08 billion in cash at the end of 2020, borrowed $1.3 billion to help finance the transaction. Astrazeneca plc also enabled the deal by agreeing to divest its 26.7% share in Viela Bio for a profit of between $760 million and $780 million.
Days after going public, Viela Bio Inc. nailed down a deal with Mitsubishi Tanabe Pharma Corp. to develop and commercialize Viela’s humanized anti-CD19 monoclonal antibody, inebilizumab, in nine Asia regions for the rare disease called neuromyelitis optica spectrum disorder (NMOSD), as well as other potential future indications.
Days after going public, Viela Bio Inc. nailed down a deal with Mitsubishi Tanabe Pharma Corp. to develop and commercialize Viela's humanized anti-CD19 monoclonal antibody, inebilizumab, in nine Asia regions for the rare disease called neuromyelitis optica spectrum disorder (NMOSD), as well as other potential future indications.
